Insights Widest with the analysis, Proactive gives perspectives that others don't.

Atai Life Sciences - Psychedelic medicines: Startups and innovators set the pace on trip to pharmaceutical mainstream

Taking the active ingredients of psychedelics and proving their effectiveness in the clinic...

22 hours, 44 minutes ago

Open Orphan coronavirus test launch underpins 19p share price target, says...

The City broker left its forecasts unchanged but said there is room for upside depending on...

1 day ago

Oncimmune is building momentum in key areas says broker finnCap

The City broker's forecasts are unchanged, while it has reiterated its 150p share price target

1 day, 1 hour ago
Deep dive

Oncimmune extends work with Roche on immuno-therapy biomarkers

Oncimmune is a specialist in the field of immunodiagnostics

1 day, 3 hours ago

Genedrive makes life easier for coronavirus testing labs

The diagnostics firm has been rocketing thanks to its efficient coronavirus tests, but it is...

1 day, 23 hours ago


Oncimmune CEO says they're seeing 'significant interest' in its EarlyCDT...

Oncimmune Holdings PLC's (LON:ONC) Adam Hill tells Proactive the next 18 months are expected to create substantial revenues within the EarlyCDT lung cancer test business while the pipeline of contracts within the ImmunoINSIGHTS services business is building. In a trading update covering the...

21 minutes ago

Join Proactive

Get ahead of the curve

First with the equities news

Get our market previews and stories before the main networks.

Widest with the analysis

Not just the FTSE. Read about
opportunities from the whole
equities market.

Closest to the source

Hear directors at first-hand
or meet them in person at our events.

In at the start

Watch IPOs and access on the same terms as the institutions.